Chemokines in transplant rejection

Current Opinion in Investigational Drugs

Volumn 3, Issue 3, 2002, Pages 399-405

  Haskell, Christopher A ^a   Ribeiro, Sofia ^a   Horuk, Richard ^a  

^a BAYER AG   (Germany)

Author keywords

CCR1; CCR5; Chemokine; CXCR3; CXCR4 transplantation

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CTCE 0019; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EP 01013276; FINGOLIMOD; GLUCOCORTICOID; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANTES; TACROLIMUS; THERMOZYMOCIDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS CHEMOKINE BINDING PROTEIN; VT 200; WO 00039125; WO 00056729; WO 00076993; WO 00116114; WO 00121177; WO 00157023; WO 0016114;

DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; EXPERIMENTAL MODEL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT; LEUKOCYTE MIGRATION; LONG TERM CARE; LUNG TRANSPLANTATION; NONHUMAN; REVIEW; SKIN GRAFT;

ANIMALS; CHEMOKINES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; RECEPTORS, CHEMOKINE; SKIN TRANSPLANTATION;

EID: 0036231274     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Chemokines: Immunology's high impact factors
2. Chemokine receptors
3. Cellular components of allograft rejection: Identity, specificity, and cytotoxic function of cells infiltrating acutely rejecting allografts
4. Chemokines and disease
5. Early and late chemokine production correlates with cellular recruitment in cardiac allograft vasculopathy
6. RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages
7. Role of RANTES in experimental cardiac allograft rejection
8. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
9. Donor-derived IP-10 initiates development of acute allograft rejection
10. Early expression of interferon-gamma inducible protein 10 and monokine induced by interferon-gamma in cardiac allografts is mediated by CD8+ T cells
11. Requirement of the chemokine receptor CXCR3 for acute allograft rejection
12. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection
13. 3CR1 reveals a role for fractalkine in cardiac allograft rejection
14. Expression of chemokines and chemokine receptors during human renal transplant rejection
15. RANTES chemokine expression in cell-mediated transplant rejection of the kidney
16. Chemokine expression during acute rejection of rat kidneys
17. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: Blocking monocyte arrest and recruitment
18. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist
19. CC chemokine receptor 5 and renal-transplant survival
20. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
21. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study
22. Early increased chemokine expression and production in murine allogeneic skin grafts is mediated by natural killer cells
23. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompability-disparate skin grafts
24. Induction of chemokine gene expression during allogeneic skin graft rejection
25. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome
26. RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration
27. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection
28. CCR1-specific non-peptide antagonist: Efficacy in a rabbit allograft rejection model
29. Preliminary data support efficacy and safety of novel lymphocyte homing agent in transplant patients
30. FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines
31. Unmet medical markets
32. Chemokine/chemokine receptor nomenclature
33. CXCR4 antagonist treatment of hematopoietic cells
34. Novel myxomal genes for immune modulation
35. Non-peptide CCR1 receptor antagonist in combination with cyclosporin A for the treatment of heart transplant rejection
36. External preparation of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or pharmaceutically acceptable salts thereof for topical administration
37. Benzene compound and pharmaceutical use thereof
38. Drug composition
39. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCR1 receptor
40. Methods for preventing graft rejection and ischemia-reperfusion injury
41. Agonist and antagonist antibodies to the chemokine receptor-2 (CCR2)
42. Azabicycloalkanes as CCR5 modulators
43. Piperidines as CCR5 modulators
44. Anilide derivative, its production and use
45. Benzazepine derivative, its production and use
46. Treating graft rejection with CCR5 inhibitors
47. Novel uses of mammalian CCR6 receptors and related reagents
48. Treating graft rejection with CXCR3 inhibitors
49. Methods for treating disease with antibodies to CXCR3
50. Compounds and methods for modulating CXCR3 function
51. Chemokine receptor binding heterocyclic compounds
52. vMIP-II peptide antagonists of CXCR4
53. Chemokine-like proteins and methods of use
54. Peptide derivative
55. Benzodiazepine-containing chemokine receptor antagonist
56. Medicine for antagonizing chemokine receptors
57. Piperidine-containing chemokine receptor antagonist
58. Chemokine/cytokine expression inhibitors
59. Chemokine receptor antagonist and cyclosporin in combined therapy